Prokarium Ltd is a clinical stage SME with a dual business model: Development of in-house oral vaccines and out-licensing of its Vaxonella oral vaccine delivery platform. Currently the focus is on a Chlamydia vaccine as well as a Clostridium difficile vaccine. Prokarium is currently funded by Flerie Invest AB, but is interested in meeting with additional investors for a £12/$20 million Series B financing to close early 2016.
If you are interested to know more about investing in Prokarium, please contact us to obtain the latest slide deck explaining the investment opportunity.
Partnering with organisations interested in using the Vaxonella® platform is also a priority for Prokarium. If you have a vaccine candidate that you want to evaluate in an oral vaccine delivery platform, with the advantages of a single manufacturing platform, strong mucosal immune response and ease of manufacture, then we can offer to clone your antigens into our platform for you to evaluate in your established preclinical models. For more details on the advantages of oral delivery using Vaxonella, see the Technology section.